2007 highlights Entered the large and growing Egyptian market through the acquisition of Alkan Pharma Strengthened our position in core markets through the acquisition of Arab Pharmaceutical Manufacturing Co. Ltd.
Entered the injectable oncology market through the acquisitions of Ribosepharm and Thymoorgan in Germany Expanded our oncology portfolio through new product acquisitions Began production in our new cephalosporin plant in Portugal for the MENA region and Europe in 2007 and for the US in early 2008 1 Launched 28 new products, received 129 approvals across all businesses and geographic regions and submitted 74 regulatory 2 filings in MENA, the US and Europe Raised gross proceeds of 81.6 million approximately $160 million in January 2008 in an equity placing of shares, funding the acquisition of APM, strengthening our balance sheet and enhancing our flexibility to finance future growth Revenue $ million Profit attributable to shareholders $ million 41.6% 14.8% 05 05 262.2 43.9 06 317.0 06 54.5 07 07 62.6 448.8 Diluted earnings per share cents Operating profit $ million 22.8% 14.2% 05 05 69.2 28.3 06 06 75.2 31.0 07 07 35.4 92.4 3 EBITDA $ million 30.1% 05 79.5 1.
New pharmaceutical compounds that are being launched for the first time by the Group 06 89.0 or for the first time within another business segment or a new region.
This includes only the first submission of new compound or line extension in a region.
Reported profit before interest, tax, depreciation and amortisation.
Hikma Pharmaceuticals PLC Annual report 2007 03 products 04 Hikma Pharmaceuticals PLC Annual report 2007 We have 353 products in 728 dosage strengths and forms being sold in 47 countries around the world.
Hikma Pharmaceuticals PLC Annual report 2007 05 With 104 new products pending approval at the end of 2007, we are building a substantial platform that will drive expansion and future profitability.
pipeline Hikma Pharmaceuticals PLC Annual report 2007 07 Our strength in the MENA region is unsurpassed.
We are developing our presence and expanding our geographic reach through organic growth and strategic acquisitions.
08 Hikma Pharmaceuticals PLC Annual report 2007 markets progress Our position as a leading speciality pharmaceutical company, with an excellent position in the MENA region, is stonger than ever.
